Gemcitabine

製品コードS1714 別名:LY-188011, NSC 613327

Gemcitabine 化学構造

分子量(MW):263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

サイズ 価格(税別) 在庫  
In DMSO JPY 23500 あり
JPY 18100 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(70)

製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
体外試験

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NFjFfHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\DV2NKSzVyPUCuNFAxPDV6IH7N M{nmOHNCVkeHUh?=
ES4 NWLY[WhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\IcWpTUUN3ME2wMlAxODZ3MzDuUS=> NEXwUHFUSU6JRWK=
ACHN MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13IUmlEPTB;MD6wNFA5QDdibl2= M3zUfnNCVkeHUh?=
KYSE-510 NVzqO2pHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYL2dVRyUUN3ME2wMlAxODl5NTDuUS=> NHHTRllUSU6JRWK=
EW-7 NH7TVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMECyOVghdk1? MUjTRW5ITVJ?
BFTC-905 M3\nO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LuRmlEPTB;MD6wNFUyPSCwTR?= MUHTRW5ITVJ?
KE-37 NWrRTIM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLqfXExUUN3ME2wMlAxPTZzIH7N M3HN[nNCVkeHUh?=
SBC-5 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\telhKSzVyPUCuNFA2PyCwTR?= NULuO3Z[W0GQR1XS
NKM-1 MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHv2[2hKSzVyPUCuNFA4ODlibl2= NWi2NlkxW0GQR1XS
RH-1 MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M133WWlEPTB;MD6wNFcyQCCwTR?= MX3TRW5ITVJ?
ALL-PO NYDoN2xLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrOR5NMUUN3ME2wMlAxQDNibl2= NFTrdGtUSU6JRWK=
QIMR-WIL NY\0[oZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7uTWM2OD1yLkCwPFk1KG6P M2WxTXNCVkeHUh?=
A375 NYnVSHdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXwTVdyUUN3ME2wMlAxQTl3IH7N NIfhOG5USU6JRWK=
SIG-M5 MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfOTWM2OD1yLkCxNFQhdk1? NXPhRYZ2W0GQR1XS
KGN NHPWS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMEGwPEBvVQ>? NELxboVUSU6JRWK=
EW-13 MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm4TWM2OD1yLkCxNVIhdk1? M37OW3NCVkeHUh?=
NCI-SNU-1 MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:4TWM2OD1yLkCxOkBvVQ>? NGjTW49USU6JRWK=
PSN1 M1uxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGO5OXdKSzVyPUCuNFE3PSCwTR?= MmDWV2FPT0WU
HUTU-80 M4r6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPRSm9KSzVyPUCuNFE3PiCwTR?= M3PySnNCVkeHUh?=
EW-16 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zSPWlEPTB;MD6wNlMhdk1? M4\y[nNCVkeHUh?=
786-0 MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mli0TWM2OD1yLkCyN{BvVQ>? M3HFW3NCVkeHUh?=
ES1 MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HH[WlEPTB;MD6wNlY5KG6P M4LFR3NCVkeHUh?=
RKO M3j5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfGTWM2OD1yLkCyO|khdk1? NUjlcFZYW0GQR1XS
ESS-1 NV:2WJpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nTWWlEPTB;MD6wNlg3KG6P NXvL[|RLW0GQR1XS
SK-UT-1 M37rSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnHPYdOUUN3ME2wMlAzQTdibl2= NEmxeGRUSU6JRWK=
LB2241-RCC Mly2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnYWlNKSzVyPUCuNFMyQCCwTR?= M2H2UXNCVkeHUh?=
CHL-1 NWq3[VBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4frbmlEPTB;MD6wN|I1KG6P NUfNNYFjW0GQR1XS
SW1783 M4rzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoG1TWM2OD1yLkCzN|Yhdk1? MWnTRW5ITVJ?
MEL-JUSO MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXOTWM2OD1yLkCzPVEhdk1? Ml3DV2FPT0WU
HT-29 NWT4bXJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPRTWM2OD1yLkC0NVMhdk1? M3i3NHNCVkeHUh?=
SNG-M NXvadlBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3j1e2lEPTB;MD6wOFI2KG6P M2HaV3NCVkeHUh?=
TE-15 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT2bIxKSzVyPUCuNFQ3PCCwTR?= MXvTRW5ITVJ?
HOS Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3noTWlEPTB;MD6wOFghdk1? M{jBWnNCVkeHUh?=
BB65-RCC MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TPXmlEPTB;MD6wOVEzKG6P MkjmV2FPT0WU
HCE-4 NW\zSJVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXy4TnV5UUN3ME2wMlA2Ojhibl2= NVTRdYFvW0GQR1XS
MHH-ES-1 NYDhNpB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwMEWzNUBvVQ>? NXLvXFBLW0GQR1XS
RPMI-7951 MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG1ZppKSzVyPUCuNFU1OSCwTR?= NUf3N2dWW0GQR1XS
IST-SL2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTvZllEUUN3ME2wMlA2QDRibl2= NWrl[WxqW0GQR1XS
CMK NHP0epFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLNTWM2OD1yLkC1PFYhdk1? NF33PGRUSU6JRWK=
GR-ST MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnOcIlKSzVyPUCuNFU6PSCwTR?= MXnTRW5ITVJ?
NALM-6 MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwME[yNkBvVQ>? NYi2blNGW0GQR1XS
RPMI-6666 NVuyblVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTHTWM2OD1yLkC2OVIhdk1? MnLQV2FPT0WU
LC-2-ad M3HLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDYVItJUUN3ME2wMlA3PTNibl2= NEHFSmtUSU6JRWK=
ARH-77 M1HHe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHHTWM2OD1yLkC3NVEhdk1? MkXwV2FPT0WU
IST-MEL1 MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1mxWGlEPTB;MD6wO|I3KG6P NEjIUVhUSU6JRWK=
SW1710 M3LwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEKwSpVKSzVyPUCuNFc2OSCwTR?= NIjqWGxUSU6JRWK=
DEL M2TrOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LNTWlEPTB;MD6wPFg4KG6P MUPTRW5ITVJ?
AGS MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTEdHU4UUN3ME2wMlA6ODJibl2= NIjmdWpUSU6JRWK=
NCI-H2122 M13MXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVe5U29uUUN3ME2wMlA6PDZibl2= NVKyUlBvW0GQR1XS
HSC-4 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMUCyJI5O NYG1bYdSW0GQR1XS
AM-38 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwMUKxJI5O NVrlUnhQW0GQR1XS
769-P NYjlTpRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPOPJRVUUN3ME2wMlEzOyCwTR?= NYCydGI2W0GQR1XS
RT-112 MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\nZmlEPTB;MD6xNlchdk1? M2\0XnNCVkeHUh?=
MCF7 NHn6SGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXDNmROUUN3ME2wMlE{PiCwTR?= MmLhV2FPT0WU
IGROV-1 MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37XXWlEPTB;MD6xOFUhdk1? M1PFenNCVkeHUh?=
OCI-AML2 M{jFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1K0UmlEPTB;MD6xOFchdk1? M{fqeXNCVkeHUh?=
NCI-H1299 NIrsPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljxTWM2OD1yLkG1O{BvVQ>? MXrTRW5ITVJ?
A431 NGHifYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjDOoo2UUN3ME2wMlE5OyCwTR?= MkDyV2FPT0WU
SW982 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3yZ3JnUUN3ME2wMlIyOyCwTR?= Mk\RV2FPT0WU
BB30-HNC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwMkOxJI5O M3vJXnNCVkeHUh?=
ACN MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXROXQ3UUN3ME2wMlI1PCCwTR?= Mn[yV2FPT0WU
647-V MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXvZYVKSzVyPUCuNlQ5KG6P Mln5V2FPT0WU
SK-PN-DW M1Llbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMk[2JI5O M4HUUnNCVkeHUh?=
LCLC-97TM1 MoW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37kdmlEPTB;MD6yOlchdk1? MmnQV2FPT0WU
LB1047-RCC NWnWPHk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TBcWlEPTB;MD6yOlkhdk1? M4\wfXNCVkeHUh?=
A2780 Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLmTWM2OD1yLkK3JI5O NYTKZmI4W0GQR1XS
C-33-A NHPqV2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPUTWM2OD1yLkK3N{BvVQ>? Mnn0V2FPT0WU
NCI-H2228 MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XZS2lEPTB;MD6zNVQhdk1? NUT3Znd7W0GQR1XS
TE-5 NF3yNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnNT3R5UUN3ME2wMlMyPiCwTR?= M2[0O3NCVkeHUh?=
HC-1 M1P5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP4XVM2UUN3ME2wMlMzPyCwTR?= M3Sze3NCVkeHUh?=
SK-MES-1 NHLVb5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX4[o9[UUN3ME2wMlMzQCCwTR?= MUnTRW5ITVJ?
NCI-H1355 NGPG[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX5[5FsUUN3ME2wMlM5OSCwTR?= MnW2V2FPT0WU
YKG-1 M3PvU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;TOYVKSzVyPUCuOFE6KG6P MlK3V2FPT0WU
RS4-11 M4TPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwNEOzJI5O NWXoNVdZW0GQR1XS
Daoy MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWT2Wm5bUUN3ME2wMlQ2PiCwTR?= M2rJVnNCVkeHUh?=
A3-KAW Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i0fWlEPTB;MD61OVEhdk1? M{TYTHNCVkeHUh?=
SK-MEL-30 NHLLcnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPZZm85UUN3ME2wMlU2PCCwTR?= MojkV2FPT0WU
U031 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHjTWM2OD1yLkW2OUBvVQ>? NWnB[FJlW0GQR1XS
SK-LMS-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwNUe4JI5O NYLVcWtpW0GQR1XS
ES6 NH3Nb5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwNUi2JI5O Mm\TV2FPT0WU
EoL-1-cell NWH5Zog{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LxW2lEPTB;MD62NVYhdk1? NWCxNWtFW0GQR1XS
NCI-H2009 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwNkG5JI5O MoDZV2FPT0WU
A4-Fuk M2jvR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[xVWlEPTB;MD62NlYhdk1? M3KwZXNCVkeHUh?=
KYSE-270 NVrUVXhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{K3PGlEPTB;MD62N|Qhdk1? MnLtV2FPT0WU
SK-LU-1 M2j0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwNkW1JI5O MkXiV2FPT0WU
SW872 NG\RfWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vtUWlEPTB;MD63OlUhdk1? NEjQT|ZUSU6JRWK=
ES8 MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzPTWM2OD1yLke4JI5O MkLEV2FPT0WU
G-402 M4izSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHETZBKSzVyPUCuO|g1KG6P NHXnfoFUSU6JRWK=
ATN-1 MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDreppKSzVyPUCuPFA4KG6P MYXTRW5ITVJ?
DoTc2-4510 NIj6RpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\tcZc1UUN3ME2wMlkxOSCwTR?= MXzTRW5ITVJ?
MES-SA NGnHTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPpTWM2OD1yLkmwOUBvVQ>? M1mybXNCVkeHUh?=
SF268 M4nmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M364UmlEPTB;MD65Nlchdk1? MUTTRW5ITVJ?
SF539 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFwMEKgcm0> M2PMXnNCVkeHUh?=
NB69 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTFwMEWgcm0> M{n6RnNCVkeHUh?=
8505C M{jsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf0V21KSzVyPUGuNFYhdk1? MUXTRW5ITVJ?
CAL-12T M1jvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\KTWM2OD1zLkC4JI5O MWXTRW5ITVJ?
BHY NVj3PY9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnCNlRWUUN3ME2xMlE1KG6P NHX0bIxUSU6JRWK=
LB647-SCLC M4D1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTFwMUigcm0> NUXMOGNPW0GQR1XS
CAL-62 NX24fI9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkP2TWM2OD1zLkKyJI5O M4eyUHNCVkeHUh?=
MEG-01 MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrCTWM2OD1zLkK3JI5O MUTTRW5ITVJ?
MG-63 NGT4OYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\FbWNKSzVyPUGuN|Mhdk1? M3f1cHNCVkeHUh?=
SW620 M3H3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojpTWM2OD1zLkO1JI5O MnfTV2FPT0WU
A388 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTFwM{[gcm0> MljuV2FPT0WU
BCPAP MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnNV25KSzVyPUGuOFUhdk1? NUnQTZFVW0GQR1XS
P30-OHK NVPRcVd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;JUotKSzVyPUGuOFYhdk1? NULrUWZ{W0GQR1XS
Ca9-22 MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\keG9KSzVyPUGuOVQhdk1? NHfDR|RUSU6JRWK=
VMRC-RCZ NFW2[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITTN|ZKSzVyPUGuOVQhdk1? NYLEV2NzW0GQR1XS
LOXIMVI NVLtUYp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWq4VmM2UUN3ME2xMlYhdk1? MYHTRW5ITVJ?
L-540 M1L6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[wVWlEPTB;MT62JI5O Ml\EV2FPT0WU
NTERA-S-cl-D1 NUHXXlZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[1cpJuUUN3ME2xMlY1KG6P M3v3b3NCVkeHUh?=
MFH-ino NY\pNmVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nVSmlEPTB;MT62OkBvVQ>? MlHpV2FPT0WU
Calu-6 NGW3e3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHTflhWUUN3ME2xMlc{KG6P NFTjR2RUSU6JRWK=
HEL NEnsO|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnvPHN5UUN3ME2xMlc6KG6P MWTTRW5ITVJ?
CAL-33 NVS2e5ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjTS4pRUUN3ME2xMlg6KG6P NFT0ZWlUSU6JRWK=
HSC-3 NVz5WndKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf3SGpKSzVyPUGuPVEhdk1? NWTzPJR4W0GQR1XS
KU812 NULa[VhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3W1[GlEPTB;MT65NUBvVQ>? MV;TRW5ITVJ?
EB2 NU\TS4NJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrFNI84UUN3ME2yMlAyKG6P NV;Hco4{W0GQR1XS
SR MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDzXpBEUUN3ME2yMlEzKG6P M4nWPHNCVkeHUh?=
NCI-H2087 M3Hzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDLN5JlUUN3ME2yMlE1KG6P NWfNT3o3W0GQR1XS
H4 Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jVOWlEPTB;Mj6xPEBvVQ>? NFryfWxUSU6JRWK=
EW-1 MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJwMkKgcm0> MUnTRW5ITVJ?
MC-IXC MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHS0RnFKSzVyPUKuNlYhdk1? M3XHcHNCVkeHUh?=
NCI-H727 NXe5TVJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfUTWM2OD1{LkWxJI5O MXnTRW5ITVJ?
MRK-nu-1 MmLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX76dYtVUUN3ME2yMlU4KG6P MoKzV2FPT0WU
COLO-668 Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HUcmlEPTB;Mj62OkBvVQ>? M2nnfHNCVkeHUh?=
CGTH-W-1 NXS5U5JOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHSZoZtUUN3ME2yMlczKG6P M4jwSXNCVkeHUh?=
CHP-212 NVjmdJVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmq2TWM2OD1{Lke1JI5O NIHCNG9USU6JRWK=
GI-1 NFjpW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDrTWM2OD1{Lke2JI5O Moq2V2FPT0WU
HCC1806 NIXVXHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV63eox4UUN3ME2yMlkyKG6P M4\PPXNCVkeHUh?=
HLE NXnoUWJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPpeXdiUUN3ME2zJI5O M{PqcHNCVkeHUh?=
HSC-2 NFXFRnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELkUFFKSzVyPUOuNFMhdk1? NWW0c4dtW0GQR1XS
DMS-273 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjjTmtJUUN3ME2zMlA4KG6P NEDJSoZUSU6JRWK=
DU-4475 NXXTe4RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTURVMzUUN3ME2zMlE1KG6P Mn\UV2FPT0WU
LXF-289 M4jnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3XU5VvUUN3ME2zMlMyKG6P MmTwV2FPT0WU
PANC-03-27 NWDvO2FKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O1R2lEPTB;Mz61NUBvVQ>? M1LQPXNCVkeHUh?=
GAMG NITYeFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X3ZWlEPTB;Mz63OEBvVQ>? MXzTRW5ITVJ?
NCI-H522 M4T1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDTTWM2OD12LkO0JI5O MkTiV2FPT0WU
SW626 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPLZnlsUUN3ME20MlQ3KG6P MnWyV2FPT0WU
HT-144 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rCVmlEPTB;ND65NkBvVQ>? NFjX[YFUSU6JRWK=
MEL-HO NVLzWoNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDoTWM2OD13LkG2JI5O M1PS[XNCVkeHUh?=
BE-13 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XV[2lEPTB;NT6yNUBvVQ>? MVvTRW5ITVJ?
VA-ES-BJ M4\Sfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnvfmhKSzVyPUWuNlYhdk1? MYjTRW5ITVJ?
NCI-H441 MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnSdHUzUUN3ME21MlYhdk1? MUPTRW5ITVJ?
KP-4 M3nMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nBbWlEPTB;NT62NUBvVQ>? MXPTRW5ITVJ?
LoVo NHi5W5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjrTWM2OD13LkexJI5O MYnTRW5ITVJ?
HT-1080 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTtdmxKSzVyPUWuPFMhdk1? M4[2TXNCVkeHUh?=
GB-1 NF3wVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTVwOESgcm0> M1PrenNCVkeHUh?=
IA-LM NIrZeJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HBZWlEPTB;NT65NUBvVQ>? M17uc3NCVkeHUh?=
8-MG-BA MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\k[mlEPTB;NT65N{BvVQ>? NYHNOVJVW0GQR1XS
SK-HEP-1 NH\LVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj2bXZKSzVyPU[uNVQhdk1? NWLyVW17W0GQR1XS
697 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fYWmlEPTB;Nj6yOUBvVQ>? NXTEPVk2W0GQR1XS
KYSE-450 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorXTWM2OD14LkOyJI5O MoXrV2FPT0WU
HCC2998 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTZwM{Sgcm0> NHnseHZUSU6JRWK=
HD-MY-Z MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHaRXZyUUN3ME22MlY5KG6P M3vFdHNCVkeHUh?=
OS-RC-2 MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrBWZdKSzVyPU[uOlghdk1? NV\Y[2RbW0GQR1XS
SF126 MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTdwMEWgcm0> NXzQU5NyW0GQR1XS
Ca-Ski M{C4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjNVoxKSzVyPUeuNFkhdk1? MWTTRW5ITVJ?
NCI-H358 NYHLTYo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnKPVFrUUN3ME23MlE3KG6P MVXTRW5ITVJ?
J82 NFnrWmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTdwNEGgcm0> M2O4fXNCVkeHUh?=
NCI-H2342 NFHNfZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTdwNkOgcm0> MkDNV2FPT0WU
OVCAR-8 MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXvTWM2OD15Lkmgcm0> NVvtZ4dmW0GQR1XS
TE-8 NVzl[ZI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7DTWM2OD16IH7N MYnTRW5ITVJ?
ETK-1 MnfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRThwMEigcm0> NXS0dFh{W0GQR1XS
HAL-01 MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkC2TWM2OD16LkKgcm0> M1XlTnNCVkeHUh?=
KYSE-150 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGmzU5BKSzVyPUiuOFchdk1? M37JOHNCVkeHUh?=
NCI-H810 M2GySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL0TWM2OD16LkW2JI5O NHPTVFRUSU6JRWK=
ONS-76 M2T4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXUTWM2OD16Lk[4JI5O NXu3WFVoW0GQR1XS
NMC-G1 NFv2VlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;zVmlEPTB;OD63OkBvVQ>? NFzWSZZUSU6JRWK=
C3A NGnaNHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLuR2ZKSzVyPUiuPFQhdk1? NHPPdndUSU6JRWK=
PA-1 NGjEOHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;XPZdKSzVyPUiuPVkhdk1? MYrTRW5ITVJ?
SH-4 NHnHN2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvkTWM2OD17LkCyJI5O MmLCV2FPT0WU
EFO-27 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHqc4tKSzVyPUmuNFUhdk1? NGfPTmlUSU6JRWK=
CAPAN-1 M4D2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTVTWM2OD17LkKzJI5O NGLSTnlUSU6JRWK=
DU-145 MlPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlq1TWM2OD17LkK5JI5O MoP3V2FPT0WU
A101D NV:0S4xYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTlwM{egcm0> NUPjPYRCW0GQR1XS
ST486 Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFyxZWFKSzVyPUmuOFEhdk1? NEDPN4NUSU6JRWK=
NCI-H1437 MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTlwNEKgcm0> MYnTRW5ITVJ?
HGC-27 Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGX4UmFKSzVyPUmuOkBvVQ>? MYLTRW5ITVJ?
8305C NILQRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vudGlEPTB;OT62OEBvVQ>? MVvTRW5ITVJ?
OCUB-M NG\uXGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzXelJ5UUN3ME2xNE4xOyCwTR?= NILQOVBUSU6JRWK=
COLO-679 M{f0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LNcmlEPTB;MUCuNFchdk1? NGToUmJUSU6JRWK=
Detroit562 MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G0VGlEPTB;MUCuOFIhdk1? MWLTRW5ITVJ?
A204 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXvR|lKSzVyPUGxMlE3KG6P Mn7pV2FPT0WU
NCI-H1734 M4Kzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmKzTWM2OD1zMT6yPUBvVQ>? NGDYfHJUSU6JRWK=
MC-CAR M2nhR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XlcmlEPTB;MUGuOVghdk1? Mm\JV2FPT0WU
NCI-H2170 NF\ZSWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr2TWM2OD1zMT65O{BvVQ>? NYPZWnlmW0GQR1XS
NCI-SNU-5 NGfHWIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInNbVNKSzVyPUGyMlE{KG6P M2HYUHNCVkeHUh?=
HCE-T MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVX4cJJmUUN3ME2xNk41OiCwTR?= NEjWeJVUSU6JRWK=
KYSE-180 MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTF{LkixJI5O NWLHcm9sW0GQR1XS
C8166 NWfobYRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DTT2lEPTB;MUOuNFghdk1? MUjTRW5ITVJ?
NCI-H460 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTF|LkW0JI5O Mn\QV2FPT0WU
SNU-449 NYe2S4prT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTF|Lke3JI5O MnrXV2FPT0WU
MDA-MB-468 NIXUWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXu1Sox{UUN3ME2xOE4yOiCwTR?= NIHWTYtUSU6JRWK=
COR-L23 MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmGzTWM2OD1zND6xN{BvVQ>? NWr4XlZIW0GQR1XS
CTV-1 NW\PdVRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2C5fmlEPTB;MUSuNVQhdk1? NVzmcmE2W0GQR1XS
BL-41 MlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF2LkO3JI5O M1jXWHNCVkeHUh?=
IGR-1 Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj4WmlKSzVyPUG0MlQzKG6P M1fydnNCVkeHUh?=
TK10 NWnvZop{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjYT2ZKSzVyPUG0MlQ6KG6P MnH5V2FPT0WU
REH MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF2LkWxJI5O NF\WfYpUSU6JRWK=
LU-139 M3vzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFO0dHZKSzVyPUG0MlU6KG6P Mm\uV2FPT0WU
KP-N-YS Mm\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvLSGhvUUN3ME2xOE46PyCwTR?= M{G1OHNCVkeHUh?=
PANC-10-05 NX;4VWFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn1d5ZPUUN3ME2xOU4{QCCwTR?= MUPTRW5ITVJ?
HL-60 NYfOS2MzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\CTWM2OD1zNT62PUBvVQ>? MkCyV2FPT0WU
T84 M1q3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXixOIIzUUN3ME2xOU46PiCwTR?= MVTTRW5ITVJ?
RPMI-8226 M1S0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\qd2RKSzVyPUG2MlAzKG6P NUj3e4tIW0GQR1XS
UM-UC-3 NFLtWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDiSIJKSzVyPUG2MlE3KG6P M4nGTXNCVkeHUh?=
TE-10 NGrzO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPjcI95UUN3ME2xOk4zOSCwTR?= Mn2wV2FPT0WU
CAL-148 NUHLN5h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zmZ2lEPTB;MUeuNlMhdk1? MXrTRW5ITVJ?
BV-173 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF5LkK3JI5O MofqV2FPT0WU
Calu-3 NUS5[GNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXxfWNKSzVyPUG3MlI6KG6P MVTTRW5ITVJ?
RPMI-2650 Ml71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTF5LkW5JI5O M4XxR3NCVkeHUh?=
MKN45 NEfxeYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTF5LkezJI5O M{XjRnNCVkeHUh?=
NUGC-3 NH\Oe5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjTToZmUUN3ME2xPE4{PCCwTR?= NUXISmNEW0GQR1XS
NCI-H520 NVrNeXJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHWcGNFUUN3ME2xPE44PyCwTR?= MmTTV2FPT0WU
CCRF-CEM NEK0XodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3RdFZKSzVyPUG4Mlg2KG6P MV\TRW5ITVJ?
NCI-H2405 MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\wZXN7UUN3ME2xPU4yKG6P NGfVOnVUSU6JRWK=
ES7 MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXmT4RsUUN3ME2xPU44PiCwTR?= NV3FVGR7W0GQR1XS
BPH-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjLc|IxUUN3ME2yNE4zQCCwTR?= NX3mTmxuW0GQR1XS
SAS NYLQUmxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[yVIFKSzVyPUKwMlUhdk1? MmL4V2FPT0WU
HuCCT1 NYDLe2Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLwNItKSzVyPUKwMlU5KG6P Ml[5V2FPT0WU
LOUCY M161eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PCd2lEPTB;MkCuOlYhdk1? M1;rTXNCVkeHUh?=
NCI-H292 MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjjVYFtUUN3ME2yNE44QSCwTR?= M360VHNCVkeHUh?=
G-361 MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DnemlEPTB;MkGuNFchdk1? NXjZXGxLW0GQR1XS
M059J NEnO[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXKTWM2OD1{MT6wPEBvVQ>? MWHTRW5ITVJ?
NCI-H1651 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfTcG5xUUN3ME2yNU4yOSCwTR?= NXjjZWhKW0GQR1XS
KALS-1 MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTJzLkO5JI5O NVzIb5oyW0GQR1XS
DJM-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJzLkW5JI5O MXTTRW5ITVJ?
AU565 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;ZV4hKSzVyPUKxMlg{KG6P NX\qdVhYW0GQR1XS
HCC38 NFjWNplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTJzLkm1JI5O NUnmd202W0GQR1XS
U251 M1Wxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfSfW5bUUN3ME2yNk4zPyCwTR?= NXjLc45{W0GQR1XS
ABC-1 NUfNe2F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHYfYdKSzVyPUKyMlY2KG6P MXrTRW5ITVJ?
SK-NEP-1 MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvWTWM2OD1{Mj65N{BvVQ>? M4LUVXNCVkeHUh?=
CESS NFjxeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nuSWlEPTB;MkOuNVkhdk1? NV\JSI5yW0GQR1XS
MIA-PaCa-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPy[pRKSzVyPUKzMlM3KG6P MVrTRW5ITVJ?
SUP-T1 NEPVWnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXLcoJHUUN3ME2yN{41PyCwTR?= M3fXN3NCVkeHUh?=
L-428 NXuzW|NUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[xRmlEPTB;MkOuOlIhdk1? MkjCV2FPT0WU
SW954 NYe3Oo42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHJNmZKSzVyPUKzMlY5KG6P MUjTRW5ITVJ?
HO-1-N-1 M{HLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3lcW9pUUN3ME2yN{44PyCwTR?= NFrsWYlUSU6JRWK=
CHP-126 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n6OWlEPTB;MkSuNVQhdk1? MmfwV2FPT0WU
HMV-II M1HyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJ2LkO0JI5O MV3TRW5ITVJ?
NB10 NXfOOJVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rpZWlEPTB;MkSuN|chdk1? MljJV2FPT0WU
A172 M3;Scmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofaTWM2OD1{ND63NUBvVQ>? MULTRW5ITVJ?
MONO-MAC-6 NXnvbIhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DRW2lEPTB;MkSuPFQhdk1? MlHLV2FPT0WU
NCI-H1650 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTJ3LkSgcm0> MV\TRW5ITVJ?
NH-12 NGXqeolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJ3LkWgcm0> MmT1V2FPT0WU
ML-2 MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\Zd|dEUUN3ME2yOU44PCCwTR?= MkTHV2FPT0WU
MZ2-MEL NYL1OnFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLCTWM2OD1{Nj6yNkBvVQ>? NUfwbI9pW0GQR1XS
COLO-684 NIP1c5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJ4LkSxJI5O M4X5WHNCVkeHUh?=
HuP-T4 MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC4TWM2OD1{Nz6zJI5O Mnv5V2FPT0WU
SW837 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXp[GdlUUN3ME2yO{43OiCwTR?= NFzWPIdUSU6JRWK=
MDA-MB-231 NF64ZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\lXHl[UUN3ME2yO{44QCCwTR?= NHnnUXpUSU6JRWK=
KYSE-140 NF3Pc3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTJ5LkmxJI5O NFuzc3FUSU6JRWK=
NOMO-1 NWPUUGNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETGO3hKSzVyPUK4MlY5KG6P NVnGPY1jW0GQR1XS
GP5d MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJ6LkeyJI5O NGGwZW1USU6JRWK=
COR-L105 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3WwZWlEPTB;MkmuOFIhdk1? MorUV2FPT0WU
LS-411N NYDzOFl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJ7Lki4JI5O MV;TRW5ITVJ?
NY Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DGVGlEPTB;M{CuNVghdk1? M1rRSXNCVkeHUh?=
NCI-H2030 NIXZPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVeyc5BtUUN3ME2zNE41PSCwTR?= MoDVV2FPT0WU
CCF-STTG1 M33wb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH4O5Q2UUN3ME2zNU41OiCwTR?= MYPTRW5ITVJ?
NCI-H1703 M{nsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\BOmlEPTB;M{GuO|ghdk1? NF\q[o1USU6JRWK=
TUR M{jXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jTOGlEPTB;M{KuNFMhdk1? MY\TRW5ITVJ?
NOS-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jJVWlEPTB;M{KuOFQhdk1? MnfGV2FPT0WU
A2058 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TsUGlEPTB;M{KuPFMhdk1? NFfke4pUSU6JRWK=
LCLC-103H NWThS5JqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ewcGlEPTB;M{OuNlUhdk1? M4nrd3NCVkeHUh?=
NCI-H510A MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfIPJNQUUN3ME2zN{4zPyCwTR?= NH2ycFZUSU6JRWK=
BC-1 NHT6dmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTTd4RKSzVyPUOzMlc4KG6P M{TkbnNCVkeHUh?=
SK-CO-1 NVL2bZlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHJbHV3UUN3ME2zOE4xOSCwTR?= M1ezOnNCVkeHUh?=
A673 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTN2LkG3JI5O M4LGRXNCVkeHUh?=
VM-CUB-1 MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe5PYxKSzVyPUO0MlY6KG6P M1;OR3NCVkeHUh?=
HH NIXM[3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPYTWM2OD1|NT6wOkBvVQ>? NYHwV2xCW0GQR1XS
CAL-27 M3zWTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1n1bGlEPTB;M{WuNVYhdk1? MUXTRW5ITVJ?
NEC8 MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf0NVRKUUN3ME2zOU4{PyCwTR?= NXTFeHZ1W0GQR1XS
BxPC-3 NG\RNmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrUWoJKSzVyPUO2MlkyKG6P NGOzZmVUSU6JRWK=
SNB75 MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTFTWM2OD1|Nz6yOEBvVQ>? MkL1V2FPT0WU
NB13 Mo\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3e1WmlEPTB;M{iuNlMhdk1? M1TrfHNCVkeHUh?=
SK-OV-3 MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTN6Lke0JI5O NEizZldUSU6JRWK=
ME-180 Mo\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjYW|E4UUN3ME2zPE45KG6P NHnyUJpUSU6JRWK=
JiyoyeP-2003 NWPM[VdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPTc5RKSzVyPUO5MlM5KG6P NW\tUWhMW0GQR1XS
LU-134-A NEnxVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\2eGJKSzVyPUSwMlAzKG6P MoT5V2FPT0WU
LS-123 NYLjco9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X0[WlEPTB;NECuNlghdk1? NILwRmtUSU6JRWK=
COLO-800 MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;vfWtKSzVyPUSwMlU3KG6P NHq4fGRUSU6JRWK=
LB831-BLC NHHaO5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTRzLki1JI5O M{npTHNCVkeHUh?=
NCI-H747 NWC1W2x5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv0TWM2OD12Mj6yPEBvVQ>? MkHoV2FPT0WU
MZ7-mel NIrLWGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7jbYF7UUN3ME20Nk43PiCwTR?= M2jKWHNCVkeHUh?=
GT3TKB NXXHRlRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mli5TWM2OD12Mj63NkBvVQ>? NX3X[YtQW0GQR1XS
MOLT-16 MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPYTWM2OD12Mz6wOUBvVQ>? MUjTRW5ITVJ?
23132-87 MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXITWM2OD12Mz6wOUBvVQ>? NUDy[HR6W0GQR1XS
PF-382 M2WzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLOTWM2OD12ND6yNkBvVQ>? M3zDV3NCVkeHUh?=
ES3 M{Tudmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrTdY9KSzVyPUS0MlYhdk1? MoTlV2FPT0WU
SW756 MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPSTWM2OD12NT6xOEBvVQ>? NXS4eHN4W0GQR1XS

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p70S6K1 / p-S6 / HIF-1α ; 

PubMed: 27765914     


Cells were treated with different doses of gemcitabine (0, 1.5 and 2.5 μM), the expression levels of p70S6K1, p-S6 and HIF-1α were determined by Western blotting. GAPDH is used as an internal control.

PARP / Cleaved PARP / Cleaved caspase-3 / phopho-p38 / p38 / p-JNK / JNK / p-c-Jun; 

PubMed: 24409315     


AsPC-1, BxPC-3, and COLO-357 cells were incubated for the indicated times with 100 ng/ml, 10 ng/ml, and 5 ng/ml gemcitabine, respectively, and analyzed by immunoblotting. 

27765914 24409315
Immunofluorescence
Bim1; 

PubMed: 27177084     


Gemcitabine enhanced nuclear accumulation of Bmi1 by immunofluorescence staining. The graphs shown are representative results of three independently repeated experiments. Scale bar, 50 μm.

27177084
Growth inhibition assay
Cell viability; 

PubMed: 27765914     


A and B. Pancreatic adenocarcinoma cells Bxpc-3 (A) and Panc-1 (B) were treated with gemcitabine (GEM) for 48 h at different doses. The cell viability was analyzed by CCK-8 assay, and normalized to cells without gemcitabine treatment. 

27765914
体内試験 Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
water (warmed)
混合させたのち直ちに使用することを推奨します。
52mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 263.2
化学式

C9H11F2N3O4

CAS No. 95058-81-4
保管
in solvent
別名 LY-188011, NSC 613327

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04051047 Not yet recruiting Drug: Gemcitabine|Procedure: Tumor biopsy and blood draw Glial Tumor of Brain|Diffuse Intrinsic Pontine Glioma|Glioma University of Michigan Rogel Cancer Center|University of Colorado Denver November 30 2019 Early Phase 1
NCT03669601 Not yet recruiting Drug: AZD6738|Drug: Gemcitabine Cancer CCTU- Cancer Theme|AstraZeneca|Cambridge University Hospitals NHS Foundation Trust September 30 2019 Phase 1
NCT04046887 Not yet recruiting Drug: Lonsurf|Drug: Gemcitabine|Drug: Nab-Paclitaxel Pancreatic Cancer|Pancreatic Ductal Adenocarcinoma Patrick Joseph Loehrer Sr.|Indiana University|Taiho Oncology Inc. August 2019 Phase 1
NCT03865563 Not yet recruiting Drug: Retrograde venous infusion of gemcitabine/lipiodol Pancreatic Adenocarcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins July 2019 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • 回答:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

Tags: Gemcitabine を買う | Gemcitabine ic50 | Gemcitabine 供給者 | Gemcitabine を購入する | Gemcitabine 費用 | Gemcitabine 生産者 | オーダーGemcitabine | Gemcitabine 化学構造 | Gemcitabine 分子量 | Gemcitabine 代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID